Class Action Lawsuit Filed Against Aquestive Therapeutics Over Alleged Misstatements About Drug Approval Timeline
A class action lawsuit has been filed against Aquestive Therapeutics, Inc. (NASDAQ: AQST) alleging that the company and its officers made misleading statements about the timeline for approval of its drug Anaphylm. The lawsuit claims that the company overstated the likelihood and timing of regulatory approval, which may have caused investor harm. The case is ongoing, and affected investors are encouraged to join the lawsuit.
Tickers: $AQST
Topics: Aquestive Therapeutics class action NDA regulatory approval securities fraud